Items Tagged ‘anaplastic astrocytoma’

July 16th, 2015

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma


Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioblastoma, which includes both glioblastoma multiforma and anaplastic astrocytoma. A clinical study called Toca 5 will be initiated later this year […]

View full entry

Tags: anaplastic astrocytoma, Brain Cancer, General Brain Cancer, glioblastoma multiforma, immune-oncology, News, Toca 5, Toca 511, Toca FC